India’s pharmaceutical and healthcare sector witnessed a robust surge in deal-making activity in the third quarter of 2025 (July–September), marking one of its strongest quarters in recent years. According to a report by Grant Thornton Bharat, the sector recorded 72 transactions valued at $3.5 billion, reflecting renewed investor confidence in India’s life sciences and healthcare ecosystem.
Sharp Rise in Deal Value and Volume
The sector saw a 28% rise in deal volume and a 166% surge in total deal value compared to the previous quarter (Q2 2025), which registered 56 deals worth $788 million. Of the $3.5 billion recorded in Q3, private deals—including mergers and acquisitions (M&A) and private equity (PE) transactions—accounted for nearly $3 billion across 68 deals, underscoring strong interest from both strategic and financial investors.
M&A Activity Drives Growth
While PE deal volumes saw a slight 3% decline compared to Q2, M&A activity jumped 57%, signaling a clear shift toward consolidation and strategic scale-ups. Grant Thornton Bharat attributed this surge to seven high-value deals worth $2.6 billion, highlighting investors’ appetite for large-scale transactions in the pharma, biotech, and hospital segments.
Capital Market Activity Picks Up
The quarter also saw renewed momentum in public market activity with three initial public offerings (IPOs) worth $428 million and one qualified institutional placement (QIP) valued at $88 million. These offerings reflected growing optimism in the sector’s growth outlook, particularly in light of India’s expanding healthcare demand and innovation-driven business models.
Pharma and Biotech Lead the Charge
Pharma and biotech segments emerged as the top performers, accounting for 29% of total deal volume. The report noted a strategic shift from API (Active Pharmaceutical Ingredients) to formulations, contract drug manufacturing operations (CDMOs), and research-led platforms, signaling investor preference for integrated, innovation-driven models.
Major Highlight: Torrent Pharma–JB Chemicals Deal
The standout deal of the quarter was Torrent Pharmaceuticals’ $1.4 billion acquisition of a 46% stake in JB Chemicals and Pharmaceuticals. The landmark transaction not only strengthened Torrent’s presence in chronic care markets but also underscored the sector’s ongoing wave of strategic consolidations aimed at expanding product portfolios and therapeutic capabilities.
Investor Focus Expands Across Healthtech and Wellness
Deal activity also remained strong in healthtech, wellness, and pharma services, with investors showing clear interest in early- and mid-stage innovation-led companies. The diversity of transactions indicates a broad-based confidence in the digital transformation and consumer health evolution within India’s healthcare ecosystem.
Positive Outlook for India’s Life Sciences Sector
Bhanu Prakash Kalmath S J, Partner and Healthcare Industry Leader at Grant Thornton Bharat, said, “Q3 marked a resurgence in deal activity, driven by a healthy mix of scale, capability, and innovation-led investments. The momentum in pharma and biotech, supported by strategic consolidations, signals growing confidence in India’s life sciences potential.” As reported by business-standard.com, as India positions itself as a global hub for pharmaceutical innovation and healthcare delivery, the surge in deal activity underscores the sector’s resilience, adaptability, and long-term growth prospects.
